Corbus Pharmaceuticals Holdings, Inc. (CRBP) · Oct 15, 2026 · Other events
Pipeline update — CRB-913 5% weight loss; CRB-701 43% OPSCC ORR
Corbus’ clinical update fills in CRB-913 obesity and CRB-701 cancer data, but mostly confirms milestones already known to investors.
Corbus is a clinical-stage biotech advancing two main assets: CRB-701 toward a registrational throat-cancer study and CRB-913 toward Phase 2 obesity development. The broad setup was already public through the company’s second-quarter update and the September 14, 2026 CANYON-1 topline release, so this presentation is mainly a fuller investor narrative rather than a fresh catalyst.
CRB-701 remains the more advanced business opportunity. The presentation highlights 42.9% confirmed response in second-line OPSCC at the 3.6 mg/kg dose, with median progression-free survival of 5.6 months, and 34.4% response in cervical cancer at the same dose. Those figures support the company’s decision to move into TEMPO-1, but they remain small, non-randomized Phase 1/2 data rather than registration-grade evidence. 〔0〕
| Program / setting | Key figure | What it means |
|---|---|---|
| CRB-701, OPSCC, 3.6 mg/kg | 42.9% cORR; 5.6-month PFS | Supports the registrational dose |
| CRB-701, cervical cancer, 3.6 mg/kg | 34.4% cORR; 4.3-month PFS | Potential differentiation versus existing second-line treatment |
| CRB-913, 60 mg | 5.0% placebo-adjusted weight loss at 12 weeks | Establishes a clinical signal for Phase 2 |
| Cash, cash equivalents and investments | Approximately $118 million at June 30, 2026 | Provides funding visibility, though not a complete development budget |
CRB-913 clears the first hurdle, but not the commercial one. The 5% placebo-adjusted weight loss at 12 weeks, with no apparent plateau, gives Corbus a reason to advance its non-incretin oral obesity program. The safety framing is encouraging in the short study, but the comparison with GLP-1 drugs is cross-trial and the program still needs longer-duration data showing whether weight loss persists and tolerability holds.
The presentation mostly confirms an already-known milestone path. TEMPO-1 had already been expected to start in September 2026, CRB-701 plus pembrolizumab data are targeted for the first quarter of 2027, and the CRB-913 Phase 2 monotherapy study is expected in the first half of 2027. 〔1〕 〔2〕
Bottom line: This is a substantive pipeline refresh, but not a major expectation reset. It strengthens the case that both programs are progressing, while leaving the next meaningful proof points—registrational CRB-701 data and longer-term CRB-913 efficacy and safety—still ahead.
ObesityWeek presentation, November 14–17, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!